Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1962 1
1964 1
1968 1
1969 2
1971 1
1973 2
1974 1
1977 2
1978 1
1980 1
1981 5
1982 4
1983 5
1984 7
1985 17
1986 12
1987 21
1988 12
1989 9
1990 12
1991 13
1992 18
1993 18
1994 16
1995 17
1996 16
1997 20
1998 19
1999 18
2000 12
2001 19
2002 23
2003 29
2004 16
2005 30
2006 28
2007 24
2008 26
2009 26
2010 35
2011 40
2012 39
2013 45
2014 37
2015 48
2016 43
2017 50
2018 48
2019 51
2020 64
2021 79
2022 66
2023 57
2024 55
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,147 results

Results by year

Filters applied: . Clear all
Page 1
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: hagiwara k. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: hagiwara k. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
Semiology of insular lobe seizures.
Isnard J, Hagiwara K, Montavont A, Catenoix H, Mazzola L, Ostrowsky-Coste K, Guenot M, Rheims S. Isnard J, et al. Among authors: hagiwara k. Rev Neurol (Paris). 2019 Mar;175(3):144-149. doi: 10.1016/j.neurol.2018.12.002. Epub 2019 Jan 30. Rev Neurol (Paris). 2019. PMID: 30711221 Review.
Radiation Ileitis Leading to Enterovesical Fistula.
Hokama A, Kanemoto M, Hagiwara K, Ikemura A, Koga E, Tameda S, Oishi Y, Tabata S, Miyazato K, Fujita J. Hokama A, et al. Among authors: hagiwara k. Chonnam Med J. 2022 May;58(2):77-78. doi: 10.4068/cmj.2022.58.2.77. Epub 2022 May 25. Chonnam Med J. 2022. PMID: 35677948 Free PMC article. No abstract available.
Neonatal pemphigus vulgaris.
Gushi M, Yamamoto Y, Mine Y, Awazawa R, Nonaka K, Taira K, Asato Y, Hagiwara K, Uezato H. Gushi M, et al. Among authors: hagiwara k. J Dermatol. 2008 Aug;35(8):529-35. doi: 10.1111/j.1346-8138.2008.00515.x. J Dermatol. 2008. PMID: 18789074 Review.
Pulmonary alveolar microlithiasis: review and management.
Tachibana T, Hagiwara K, Johkoh T. Tachibana T, et al. Among authors: hagiwara k. Curr Opin Pulm Med. 2009 Sep;15(5):486-90. doi: 10.1097/MCP.0b013e32832d03bb. Curr Opin Pulm Med. 2009. PMID: 19617834 Review.
1,147 results